26 completed, 11 unknown, 7 terminated, 2 active not recruiting. 52 Phase 2, 5 Phase 1, 4 Phase 3.
Follow Gallbladder Cancer: new trials by email Literature Review of Gallbladder Cancer trials Research Report on Gallbladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer AK112, Gemcitabine, Cisplatin - Gallbladder Cancer | Phase 2 | Not yet recruiting | First Affiliated Hospital Xi'an Jiaotong University | 22 | 2026-08-28 | 2026-08-17 |
| Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer Trifluridine/tipiracil, Oxaliplatin - Biliary Tract Cancer, Biliary Tract Neoplasms | Phase 2 | Suspended | Case Comprehensive Cancer Center | 27 | 2025-12-01 | 2026-10-20 |
| Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer Capecitabine, Toripalimab - Gallbladder Cancer, Hilar Cholangiocarcinoma | Phase 2 | Active not recruiting | Tianjin Medical University Cancer Institute and Hospital | 110 | 2024-11-12 | 2024-12-05 |
| Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors MDX2001 - Biliary Tract Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 330 | 2024-06-12 | 2026-10-15 |
| Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT) Gemcitabine nab-PaclitaxelLenvatinibTislelizumab - Gallbladder Cancer, Cholangiocarcinoma | Phase 2 | Enrolling by invitation | Wei Gong | 44 | 2024-06-01 | 2025-05-08 |
| Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer HAIC, Surufatinib, Tislelizumab - Carcinoma, Intrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 41 | 2023-11-01 | 2023-11-18 |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors certepetide, Durvalumab, Cisplatin - Cholangiocarcinoma, Gallbladder Cancer | Phase 2 | Completed | Lisata Therapeutics, Inc. | 66 | 2023-05-13 | 2026-09-28 |
| Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC Envafolimab+Gemox - Gallbladder Cancer | Phase 2 | Unknown | Eastern Hepatobiliary Surgery Hospital | 30 | 2023-03-17 | 2023-09-15 |
| Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab - Gallbladder Cancer, Initially Unresectable | Phase 2 | Recruiting | Lu Wang, MD, PhD | 50 | 2022-12-22 | 2023-03-07 |
| Addition of Everolimus to Standard of Care in Carcinoma Gallbladder Everolimus 10 mg, Standard of care - Gallbladder Cancer | Phase 2 / Phase 3 | Unknown | Banaras Hindu University | 56 | 2022-11-01 | 2024-08-13 |
| To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | TransThera Sciences (Nanjing), Inc. | 84 | 2022-04-13 | 2025-06-12 |
| Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors TT-00420, Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | TransThera Sciences (Nanjing), Inc. | 203 | 2021-03-14 | 2024-04-26 |
| Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Seribantumab - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 2 | Terminated | Elevation Oncology | 54 | 2020-09-29 | 2025-04-03 |
| Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer Chemotherapy, Observation, Immunotherapy - Biliary Tract Cancer, Extrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Sun Yat-sen University | 92 | 2020-06-01 | 2020-06-23 |
| Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer Durvalumab + Gem/Cis, Gem/Cis - Biliary Tract Neoplasms, Gallbladder Cancer | Phase 2 | Active not recruiting | Asan Medical Center | 45 | 2020-05-20 | 2025-01-28 |
| Pembrolizumab in Biliary Tract Cancer Pembrolizumab, Cisplatin, Gemcitabine - Biliary Tract Cancer, Metastatic Cancer | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 50 | 2020-01-07 | 2023-11-03 |
| Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC M7824, Placebo, Gemcitabine - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 / Phase 3 | Terminated | EMD Serono Research & Development Institute, Inc. | 309 | 2019-09-20 | 2023-11-14 |
| M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) M7824 - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 159 | 2019-03-26 | 2023-10-25 |
| Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration Shortened hydration time and dispensary of Akynzeo, Standard of care - Gallbladder Cancer | Phase 2 | Unknown | Imperial College Healthcare NHS Trust | 30 | 2019-01-02 | 2022-07-15 |
| Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) Pembrolizumab (MK-3475), Oxaliplatin, Capecitabine - Biliary Tract Neoplasms, Cholangiocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2017-06-14 | 2021-12-03 |
Showing 20 of 52. Sign in to see all of them.
Gallbladder Neoplasms (52) · Bile Duct Neoplasms (22) · Cholangiocarcinoma (22) · Biliary Tract Neoplasms (13) · Liver Neoplasms (13) · Carcinoma, Hepatocellular (9) · Pancreatic Neoplasms (7) · Stomach Neoplasms (5) · Colorectal Neoplasms (4) · Neoplasm Metastasis (4) · Prostatic Neoplasms (4) · Carcinoma (3) · Colonic Neoplasms (3) · Esophageal Neoplasms (3) · Neoplasms (3)
Biliary Tract Diseases (52) · Digestive System Diseases (52) · Digestive System Neoplasms (52) · Gallbladder Diseases (52) · Neoplasms by Site (52) · Neoplasms (49) · Biliary Tract Neoplasms (39) · Adenocarcinoma (31) · Neoplasms by Histologic Type (31) · Neoplasms, Glandular and Epithelial (31) · Carcinoma (28) · Bile Duct Diseases (22) · Liver Diseases (14) · Endocrine Gland Neoplasms (9) · Endocrine System Diseases (9)
Gemcitabine (19) · Cisplatin (8) · Capecitabine (6) · Oxaliplatin (6) · Fluorouracil (4) · 130-nm albumin-bound paclitaxel (3) · Sorafenib (3) · Bevacizumab (2) · Drug Therapy (2) · Erlotinib Hydrochloride (2) · Everolimus (2) · Leucovorin (2) · Standard of Care (2) · durvalumab (2) · pembrolizumab (2)
Alliance for Clinical Trials in Oncology (4) · Shanghai Jiao Tong University School of Medicine (3) · Case Comprehensive Cancer Center (2) · EMD Serono Research & Development Institute, Inc. (2) · Memorial Sloan Kettering Cancer Center (2) · SWOG Cancer Research Network (2) · TransThera Sciences (Nanjing), Inc. (2) · Washington University School of Medicine (2) · All India Institute of Medical Sciences (1) · Asan Medical Center (1) · Banaras Hindu University (1) · Brown University (1) · Charite University, Berlin, Germany (1) · Copenhagen University Hospital, Rigshospitalet (1) · Daiichi Sankyo (1)
United States (29) · China (13) · South Korea (4) · United Kingdom (4) · France (3) · Germany (3) · Italy (3) · Spain (3) · Australia (2) · Canada (2) · India (2) · Japan (2) · Taiwan (2) · Argentina (1) · Brazil (1)
Steven R. Alberts, MD (3) · Benjamin Tan, M.D. (2) · Afshin Dowlati, MD (1) · Aram Hezel, MD (1) · Ari D Baron, MD (1) · Bert Hildebrandt, MD (1) · Bruno Chauffert (1) · Changhoon Yoo, MD, PhD (1) · Dieter Koeberle, MD (1) · Edgar Ben-Josef, MD (1) · Gao-jun Teng, MD, PhD (1) · Ghassan Abou-Alfa, MD (1)
PMID 32461347, PMID 12794246, PMID 15558814, PMID 18669454, PMID 18669455, PMID 19023677, PMID 19399502, PMID 20662793, PMID 21556747, PMID 25241229, PMID 25538178, PMID 25964250, PMID 35274717, PMID 36999533, PMID 38087967, PMID 38875119, PMID 40638104, PMID 41428976, PMID 41495607
U10CA032102 (2), 2018 (1), 2019 (1), 2023 (1), P30CA008748 (1), P30CA043703 (1), U01CA063200 (1)